Grannus Therapeutics, Inc.

Grannus Therapeutics is a pre-clinical platform company focused on developing and commercializing small molecule inhibitors that selectively target individual isoforms of the Hsp90 family of chaperone proteins. By selectively targeting individual isoforms, Grannus has overcome the safety limitations of previous non-isoform selective (pan) inhibitors while delivering strong efficacy results that address current unmet medical need. Grannus’s lead program is a first-in-class Hsp90𝛽-selective inhibitor for the treatment of advanced triple negative breast (TNBC) and other solid tumors. The Grannus Team has decades of experience developing and commercializing therapeutics in academia and at leading pharmaceutical and biotechnology companies of various sizes. The company has received ~$700K in Federal and State grants and closed a $1M seed round with private investors in Feb 2021.